Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay.

BACKGROUND:Levosimendan protects rat liver against peroxidative injuries through mechanisms related to nitric oxide (NO) production and mitochondrial ATP-dependent K (mitoKATP) channels opening. However, whether levosimendan could modulate the cross-talk between apoptosis and autophagy in the liver...

Full description

Bibliographic Details
Main Authors: Elena Grossini, Kevin Bellofatto, Serena Farruggio, Lorenzo Sigaudo, Patrizia Marotta, Giulia Raina, Veronica De Giuli, David Mary, Piero Pollesello, Rosalba Minisini, Mario Pirisi, Giovanni Vacca
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4400069?pdf=render
_version_ 1828938638483783680
author Elena Grossini
Kevin Bellofatto
Serena Farruggio
Lorenzo Sigaudo
Patrizia Marotta
Giulia Raina
Veronica De Giuli
David Mary
Piero Pollesello
Rosalba Minisini
Mario Pirisi
Giovanni Vacca
author_facet Elena Grossini
Kevin Bellofatto
Serena Farruggio
Lorenzo Sigaudo
Patrizia Marotta
Giulia Raina
Veronica De Giuli
David Mary
Piero Pollesello
Rosalba Minisini
Mario Pirisi
Giovanni Vacca
author_sort Elena Grossini
collection DOAJ
description BACKGROUND:Levosimendan protects rat liver against peroxidative injuries through mechanisms related to nitric oxide (NO) production and mitochondrial ATP-dependent K (mitoKATP) channels opening. However, whether levosimendan could modulate the cross-talk between apoptosis and autophagy in the liver is still a matter of debate. Thus, the aim of this study was to examine the role of levosimendan as a modulator of the apoptosis/autophagy interplay in liver cells subjected to peroxidation and the related involvement of NO and mitoKATP. METHODS AND FINDINGS:In primary rat hepatocytes that have been subjected to oxidative stress, Western blot was performed to examine endothelial and inducible NO synthase isoforms (eNOS, iNOS) activation, apoptosis/autophagy and survival signalling detection in response to levosimendan. In addition, NO release, cell viability, mitochondrial membrane potential and mitochondrial permeability transition pore opening (MPTP) were examined through specific dyes. Some of those evaluations were also performed in human hepatic stellate cells (HSC). Pre-treatment of hepatocytes with levosimendan dose-dependently counteracted the injuries caused by oxidative stress and reduced NO release by modulating eNOS/iNOS activation. In hepatocytes, while the autophagic inhibition reduced the effects of levosimendan, after the pan-caspases inhibition, cell survival and autophagy in response to levosimendan were increased. Finally, all protective effects were prevented by both mitoKATP channels inhibition and NOS blocking. In HSC, levosimendan was able to modulate the oxidative balance and inhibit autophagy without improving cell viability and apoptosis. CONCLUSIONS:Levosimendan protects hepatocytes against oxidative injuries by autophagic-dependent inhibition of apoptosis and the activation of survival signalling. Such effects would involve mitoKATP channels opening and the modulation of NO release by the different NOS isoforms. In HSC, levosimendan would also play a role in cell activation and possible evolution toward fibrosis. These findings highlight the potential of levosimendan as a therapeutic agent for the treatment or prevention of liver ischemia/reperfusion injuries.
first_indexed 2024-12-14T02:46:27Z
format Article
id doaj.art-50e99e563b594d9a874831345ab32285
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-14T02:46:27Z
publishDate 2015-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-50e99e563b594d9a874831345ab322852022-12-21T23:19:53ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012474210.1371/journal.pone.0124742Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay.Elena GrossiniKevin BellofattoSerena FarruggioLorenzo SigaudoPatrizia MarottaGiulia RainaVeronica De GiuliDavid MaryPiero PolleselloRosalba MinisiniMario PirisiGiovanni VaccaBACKGROUND:Levosimendan protects rat liver against peroxidative injuries through mechanisms related to nitric oxide (NO) production and mitochondrial ATP-dependent K (mitoKATP) channels opening. However, whether levosimendan could modulate the cross-talk between apoptosis and autophagy in the liver is still a matter of debate. Thus, the aim of this study was to examine the role of levosimendan as a modulator of the apoptosis/autophagy interplay in liver cells subjected to peroxidation and the related involvement of NO and mitoKATP. METHODS AND FINDINGS:In primary rat hepatocytes that have been subjected to oxidative stress, Western blot was performed to examine endothelial and inducible NO synthase isoforms (eNOS, iNOS) activation, apoptosis/autophagy and survival signalling detection in response to levosimendan. In addition, NO release, cell viability, mitochondrial membrane potential and mitochondrial permeability transition pore opening (MPTP) were examined through specific dyes. Some of those evaluations were also performed in human hepatic stellate cells (HSC). Pre-treatment of hepatocytes with levosimendan dose-dependently counteracted the injuries caused by oxidative stress and reduced NO release by modulating eNOS/iNOS activation. In hepatocytes, while the autophagic inhibition reduced the effects of levosimendan, after the pan-caspases inhibition, cell survival and autophagy in response to levosimendan were increased. Finally, all protective effects were prevented by both mitoKATP channels inhibition and NOS blocking. In HSC, levosimendan was able to modulate the oxidative balance and inhibit autophagy without improving cell viability and apoptosis. CONCLUSIONS:Levosimendan protects hepatocytes against oxidative injuries by autophagic-dependent inhibition of apoptosis and the activation of survival signalling. Such effects would involve mitoKATP channels opening and the modulation of NO release by the different NOS isoforms. In HSC, levosimendan would also play a role in cell activation and possible evolution toward fibrosis. These findings highlight the potential of levosimendan as a therapeutic agent for the treatment or prevention of liver ischemia/reperfusion injuries.http://europepmc.org/articles/PMC4400069?pdf=render
spellingShingle Elena Grossini
Kevin Bellofatto
Serena Farruggio
Lorenzo Sigaudo
Patrizia Marotta
Giulia Raina
Veronica De Giuli
David Mary
Piero Pollesello
Rosalba Minisini
Mario Pirisi
Giovanni Vacca
Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay.
PLoS ONE
title Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay.
title_full Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay.
title_fullStr Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay.
title_full_unstemmed Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay.
title_short Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay.
title_sort levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis autophagy interplay
url http://europepmc.org/articles/PMC4400069?pdf=render
work_keys_str_mv AT elenagrossini levosimendaninhibitsperoxidationinhepatocytesbymodulatingapoptosisautophagyinterplay
AT kevinbellofatto levosimendaninhibitsperoxidationinhepatocytesbymodulatingapoptosisautophagyinterplay
AT serenafarruggio levosimendaninhibitsperoxidationinhepatocytesbymodulatingapoptosisautophagyinterplay
AT lorenzosigaudo levosimendaninhibitsperoxidationinhepatocytesbymodulatingapoptosisautophagyinterplay
AT patriziamarotta levosimendaninhibitsperoxidationinhepatocytesbymodulatingapoptosisautophagyinterplay
AT giuliaraina levosimendaninhibitsperoxidationinhepatocytesbymodulatingapoptosisautophagyinterplay
AT veronicadegiuli levosimendaninhibitsperoxidationinhepatocytesbymodulatingapoptosisautophagyinterplay
AT davidmary levosimendaninhibitsperoxidationinhepatocytesbymodulatingapoptosisautophagyinterplay
AT pieropollesello levosimendaninhibitsperoxidationinhepatocytesbymodulatingapoptosisautophagyinterplay
AT rosalbaminisini levosimendaninhibitsperoxidationinhepatocytesbymodulatingapoptosisautophagyinterplay
AT mariopirisi levosimendaninhibitsperoxidationinhepatocytesbymodulatingapoptosisautophagyinterplay
AT giovannivacca levosimendaninhibitsperoxidationinhepatocytesbymodulatingapoptosisautophagyinterplay